Somatic comorbidities and Alzheimer's disease treatment

Neurological Sciences

Volumn 34, Issue 9, 2013, Pages 1581-1589

  Clodomiro, Alessandra ^a   Gareri, Pietro ^a   Puccio, Gianfranco ^a   Frangipane, Francesca ^a   Lacava, Roberto ^a   Castagna, Alberto ^a   Manfredi, Valeria Graziella Laura ^a   Colao, Rosanna ^a   Bruni, Amalia Cecilia ^a  

^a ASP Catanzaro   (Italy)

Author keywords

Alzheimer's disease; Dementia; Drug treatment; Elderly; Side effects adverse events; Somatic comorbidities

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CHOLINESTERASE INHIBITOR; DIGOXIN; DONEPEZIL; GALANTAMINE; KETAMINE; MEMANTINE; PLACEBO; RIVASTIGMINE; SUXAMETHONIUM;

ABDOMINAL PAIN; ALZHEIMER DISEASE; APHASIA; ARTICLE; ATRIOVENTRICULAR BLOCK; BRADYCARDIA; CARDIOVASCULAR DISEASE; CHOLESTASIS; CHOREA; CHRONIC DRUG ADMINISTRATION; COGNITIVE DEFECT; COMBINATION CHEMOTHERAPY; COMORBIDITY; CONFUSION; CONGESTIVE HEART FAILURE; CONSTIPATION; DEGENERATIVE DISEASE; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSTONIA; FAINTNESS; FALL RISK; FALLING; FATIGUE; GASTROINTESTINAL SYMPTOM; GLAUCOMATOUS NEURODEGENERATION; HEADACHE; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HEPATITIS; HIGH RISK PATIENT; HUMAN; HYPERTENSION; HYPOTENSION; INSOMNIA; LIVER DYSFUNCTION; LUNG DISEASE; MELENA; MENTAL DISEASE; MONOTHERAPY; MOTOR DYSFUNCTION; MULTIINFARCT DEMENTIA; NARCOLEPSY; NAUSEA; NEUROPATHIC PAIN; NEUROPROTECTION; NONHUMAN; OUTCOME ASSESSMENT; PARASOMNIA; PEPTIC ULCER; PERSONALIZED MEDICINE; PISA SYNDROME; QUALITY OF LIFE; RESTLESSNESS; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SEIZURE; SICK SINUS SYNDROME; SLEEP DISORDERED BREATHING; SOMATOFORM DISORDER; SOMNOLENCE; SYNAPTIC TRANSMISSION; TOXIC HEPATITIS; UNSTABLE ANGINA PECTORIS; URINARY TRACT OBSTRUCTION; URINE INCONTINENCE; VOMITING;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; COMORBIDITY; FEMALE; FRAIL ELDERLY; HUMANS; MALE;

EID: 84885425148     PISSN: 15901874     EISSN: 15903478     Source Type: Journal    
DOI: 10.1007/s10072-013-1290-3     Document Type: Article

References (75)

1. Fang X, Shi J, Song X, Mitnitski A, Tang Z, Wang C, Yu P, Rockwood KJ (2012) Frailty in relation to the risk of falls, fractures, and mortality in older chinese adults: results from the beijing longitudinal study of aging. Nutr Health Aging 16(10):903-907. doi: 10.1007/s12603-012-0368-6
2. Bernardi L, Frangipane F, Smirne N, Colao R, Puccio G, Curcio SA, Mirabelli M, Maletta R, Anfossi M, Gallo M, Geracitano S, Conidi ME, Di Lorenzo R, Clodomiro A, Cupidi C, Marzano S, Comito F, Valenti V, Zirilli MA, Ghani M, Xi Z, Sato C, Moreno D, Borelli A, Leone RA, St George-Hyslop P, Rogaeva E, Bruni AC (2012) Epidemiology and genetics of frontotemporal dementia: a door-to-door survey in southern Italy. Neurobiol Aging 33(12):2948.e1-2948.e10. doi: 10.1016/j.neurobiolaging.2012.06.017
3. Cizza G, Bernardi L, Smirne N, Maletta R, Tomaino C, Costanzo A, Gallo M, Lewis JG, Geracitano S, Grasso MB, Potenza G, Monteleone C, Brancati G, Ho JT, Torpy DJ, Bruni AC (2011) Clinical manifestations of highly prevalent corticosteroid-binding globulin mutations in a village in southern Italy. J Clin Endocrinol Metab 96(10):E1684-E1693. doi: 10.1210/jc.2011-1321
4. Marengoni A, Winblad B, Karp A, Fratiglioni L (2008) Prevalence of chronic diseases and multimorbidity among the elderly population in Sweden. Am J Public Health 98(7):1198-1200
5. Montine TJ, Larson EB (2009) Late life dementias: does this unyielding global challenge require a broader view? JAMA 302(23):2593-2594
6. Di Carlo A, Baldereschi M, Amaducci L, Lepore V, Bracco L, Maggi S, Bonaiuto S, Perissinotto E, Scarlato G, Farchi G, Inzitari D, ILSA Working Group (2002) Incidence of dementia, Alzheimer's disease, and vascular dementia in Italy. The ILSA Study. J Am Geriatr Soc 50(1):41-48
7. Reitz C, Brayne C, Mayeux R (2011) Epidemiology of Alzheimer disease. Nat Rev Neurol 7(3):137-1352. doi: 10.1038/nrneurol.2011.2
8. Schubert CC, Boustani M, Callahan CM, Perkins AJ, Carney CP, Fox C, Unverzagt F, Hui S, Hendrie HC (2006) Comorbidity profile of dementia patients in primary care: are they sicker? J Am Geriatr Soc 54:4-9
9. Andersen F, Viitanen M, Halvorsen DS, Straume B, Engstad TA (2011) Co-morbidity and drug treatment in Alzheimer's disease. A cross sectional study of participants in the dementia study in northern Norway. BMC Geriatr 4(11):58. doi: 10.1186/1471-2318-11-58
10. Duthie A, Chew D, Soiza RL (2011) Non-psychiatric comorbidity associated with Alzheimer's disease. QJM 104(11):913-920. doi: 10.1093/qjmed/hcr118
11. Solomon A, Dobranici L, Kåreholt I, Tudose C, Lǎzǎ rescu M (2011) Comorbidity and the rate of cognitive decline in patients with Alzheimer dementia. Int J Geriatr Psychiatry 26(12):1244-1251
12. Valeriani L (2011) Management of demented patients in emergency department. Int J Alzheimers Dis 2011:840312
13. Bilotta C, Bergamaschini L, Nicolini P, Casè A, Pina G, Rossi SV, Vergani C (2012) Frailty syndrome diagnosed according to the study of osteoporotic fractures criteria and mortality in older outpatients suffering from Alzheimer's disease: a one-year prospective cohort study. Aging Ment Health 16(3):273-280. doi: 10.1080/13607863.2011.609534
14. Zuliani G, Galvani M, Prandini S, Boari B, Guerzoni F, Gallerani M (2012) Discharge diagnosis and comorbidity profile in hospitalized older patients with dementia. Int J Geriatr Psychiatry 27(3):313-320
15. Fu C, Chute DJ, Farag ES, Garakian J, Cummings JL, Vinters HV (2004) Comorbidity in dementia - an autopsy study. Arch Pathol Lab Med 128:32-38
16. Hoffmann F, van der Bussche H, Wiese B, Schon G, Koller D, eisele M, Glaeske G, Scherer M, Kaduszkiewicz H (2011) Impact of geriatric comorbidity and polypharmacy on cholinesterase inhibitors prescribing in dementia. BMC Geriatr 11:190-198
17. Amanzio M, Benedetti F, Vase L (2012) A systematic review of adverse events in the placebo arm of donepezil trials: the role of cognitive impairment. Int Psychogeriatr 24(5):698-707. doi: 10.1017/S1041610211002420
18. Mangialasche F, Solomon A, Winblad B, Mecocci P, Kivipelto M (2010) Alzheimer's disease: clinical trials and drug development. Lancet Neurol 9:702-716
19. Winblad B, Black SE, Homma A, Schwam EM, Moline M, Xu Y, Perdomo CA, Swartz J, Albert K (2009) Donepezil treatment in severe Alzheimer's disease: a pooled analysis of three clinical trials. Curr Med Res Opin 25(11):2577-2587
20. Burns A, Bernabei R, Bullock R, Cruz Jentoft AJ, Frölich L, Hock C, Raivio M, Triau E, Vandewoude M, Wimo A, Came E, Van Baelen B, Hammond GL, van Oene JC, Schwalen S (2009) Safety and efficacy of galantamine (Reminyl) in severe Alzheimer's disease (the SERAD study): a randomised, placebo-controlled, double-blind trial. Lancet Neurol 8(1):39-47
21. Farlow MR, Grossberg G, Gauthier S, Meng X, Olin JT (2010) The ACTION study: methodology of a trial to evaluate safety and efficacy of a higher dose rivastigmine transdermal patch in severe Alzheimer's disease. Curr Med Res Opin 26(10):2441-2447
22. Hsiung GY, Feldman HH (2008) Pharmacological treatment in moderate-to-severe Alzheimer's disease. Expert Opin Pharmacother 9(15):2575-2582
23. Farlow MR, Salloway S, Tariot PN, Yardley J, Moline ML, Wang Q, Brand-Schieber E, Zou H, Hsu T, Satlin A (2010) Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: a 24-week, randomized, double-blind study. Clin Ther 32(7):1234-1251. doi: 10.1016/j.clinthera.2010.06.019
24. Gotti R, Bertucci C, Andrisano V, Pomponio R, Cavrini V (2003) Study of donepezil binding to serum albumin by capillary electrophoresis and circular dichroism. Anal Bioanal Chem 377(5):875-879
25. Rozzini L, Chilovi BV, Bertoletti E, Ghianda D, Conti M, Trabucchi M, Padovani A (2008) Serum albumin level interferes with the effect of donepezil in Alzheimer's disease. Aging Clin Exp Res 20(6):509-512
26. Lopez OL, Becker JT, Saxton J, Sweet RA, Klunk W, DeKosky ST (2005) Alteration of a clinically meaningful outcome in the natural history of Alzheimer's disease by cholinesterase inhibition. J Am Geriatr Soc 53:83-87
27. Reisberg B, Doody R, Stöffler A, Schmitt F, Ferris S, Möbius HJ, Memantine Study Group (2003) Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 348(14):1333-1341
28. Clerici F, Vanacore N, Elia A, Spila-Alegiani S, Pomati S, Da Cas R, Raschetti R, Mariani C, The Memantine Lombardy Study Group (2011) Memantine effects on behaviour in moderately severe to severe Alzheimer's disease: a post-marketing surveillance study. Neurol Sci May 17 (Epub ahead of print)
29. Ballard C, Aarsland D, Walker Z, Thomas A (2012) A randomized double blind clinical trial comparing memantine and antipsychotics for the prophylaxis of behavioural and psychological symptoms in people with Alzheimer's disease. AAIC 2012, Vancouver Convention Centre, Vancouver British Columbia, Canada, abstract book
30. Boxer AL, Lipton AM, Womack K, Merrilees J, Neuhaus J, Pavlic D, Gandhi A, Red D, Martin-Cook K, Svetlik D, Miller BL (2009) An open-label study of memantine treatment in 3 subtypes of frontotemporal lobar degeneration. Alzheimer Dis Assoc Disord 23(3):211-217
31. Dantoine T, Auriacombe S, Sarazin M, Becker H, Pere JJ, Bourdeix I (2006) Rivastigmine monotherapy and combination therapy with memantine in patients with moderately severe Alzheimer's disease who failed to benefit from previous cholinesterase inhibitor treatment. Int J Clin Pract 60(1):110-118
32. Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I, Memantine Study Group (2004) Memantine treatment in patients with moderate-to-severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 291:317-324
33. Howard R, McShane R, Lindesay J, Ritchie C, Baldwin A, Barber R, Burns A, Dening T, Findlay D, Holmes C, Hughes A, Jacoby R, Jones R, Jones R, McKeith I, Macharouthu A, O'Brien J, Passmore P, Sheehan B, Juszczack E, Katona C, Hills R, Knapp M, Ballard C, Brown R, Banerjee S, Onions C, Griffin M, Adams J, Gray R, Johnson T, Bentham P, Phillips P (2012) Donepezil and memantine for moderate-to-severe Alzheimer's disease. N Engl J Med 366(10):893-903
34. Lopez OL, Becker JT, Wahed AS, Saxton J, Sweet RA, Wolk DA, Klunk W, Dekosky ST (2009) Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease. J Neurol Neurosurg Psychiatry 80(6):600-607
35. Berthier ML, Pulvermüller F, Dávila G, Casares NG, Gutiérrez A (2011) Drug therapy of post-stroke aphasia: a review of current evidence. Neuropsychol Rev 21:302-317
36. Lipton SA (2004) Failures and successes of NMDA receptor antagonists: molecular basis for the use of open-channel blockers like memantine in the treatment of acute and chronic neurologic insults. J Am Soc Exp Neurother 1:101-110
37. Goodison WV, Frisardi V, Kehoe G (2012) Calcium channel blockers and Alzheimer's disease: potential relevance in treatment strategies of metabolic syndrome. J Alzheimer Dis 29:1-14
38. Chen S-R, Samoriski G, Pan H-L (2009) Antinociceptive effects of chronic administration of uncompetitive NMDA receptor antagonists in a rat model of diabetic neuropathic pain. Neuropharmacology 57(2):121-126
39. Grande LA, O'Donnell BR, Fitzgibbon DR, Terman GW (2008) Ultra-low dose ketamine and memantine treatment for pain in an opioid-tolerant oncology patient. Anesth Analg 107:1380-1383
40. Recla JM, Sarantopoulos CD (2009) Combined use of pregabalin and memantine in fibromyalgia syndrome treatment: a novel analgesic and neuroprotective strategy? Med Hypotheses 73(2):177-183
41. Orgogozo JM, Rigaud AS, Stöffler A, Möbius HJ, Forette F (2002) Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300). Stroke 33(7):1834-1839
42. Cheung W, Guo L, Cordeiro MF (2008) Neuroprotection in glaucoma: drug-based approaches. Optom Vis Sci 85(6):406-416
43. Gareri P, Gallelli L, Ferreri Ibbadu G, Lacava R, Russo E, De Sarro G (2005) Melena following use of the cholinesterase inhibitor rivastigmine. Clin Drug Invest 25(3):215-217
44. Gill SS, Anderson GM, Fischer HD, Bell CM, Li P, Normand SLT, Rochon PA (2009) Syncope and its consequences in patients with dementia receiving cholinesterase inhibitors - a population-based cohort study. Arch Intern Med 169(9):867-873
45. Kim DH, Brown RT, Ding EL, Kiel DP, Berry SD (2011) Dementia medications and risk of falls, syncope, and related adverse events: meta-analysis of randomized controlled trials. JAGS 59:1019-1031
46. Kinnair D, Machili C, Prettyman R, Van Diepen E (2011) Cardio-vascular safety of acetyl- cholinesterase inhibitors in patients suffering from Alzheimer's disease: factors that predict poor tolerability. Int J Geriatr Psychiatry 26:328-330
47. Hernandez RK, Farwell W, Cantor MD, Lawler EV (2009) Cholinesterase inhibitors and incidence of bradycardia in patients with dementia in the veterans affairs new England healthcare system. J Am Geriatr Soc 57(11):1997-2003
48. Stephenson A, Seitz DP, Fischer HD, Gruneir A, Bell CM, Gershon AS, Fu L, Anderson GM, Austin PC, Rochon PA, Gill SS (2012) Cholinesterase inhibitors and adverse pulmonary events in older people with chronic obstructive pulmonary disease and concomitant dementia: a population-based, cohort study. Drugs Aging 29(3):213-223
49. Nagy CF, Kumar D, Cullen EI, Bolton WK, Marbury TC, Gutierrez MJ, Hutman HW, Pratt RD (2004) Steady-state pharmacokinetics and safety of donepezil HCl in subjects with moderately impaired renal function. Br J Clin Pharmacol 58(Suppl 1):18-24
50. Tiseo PJ, Foley K, Friedhoff LT (1998) An evaluation of the pharmacokinetics of donepezil HCl in patients with moderately to severely impaired renal function. Br J Clin Pharmacol 46(Suppl 1):56-60
51. Yeh SB, Yeh PY, Schenck CH (2010) Rivastigmine-induced REM sleep behavior disorder (RBD) in a 88-year-old man with Alzheimer's disease. J Clin Sleep Med 6(2):192-195
52. Schredl M, Weber B, Leins ML, Heuser I (2001) Donepezil-induced REM sleep augmentation enhances memory performance in elderly, healthy persons. Exp Gerontol 36(2):353-361
53. Schredl M, Hornung O, Regen F, Albrecht N, Danker-Hopfe H, Heuser I (2006) The effect of donepezil on sleep in elderly, healthy persons: a double-blind placebo-controlled study. Pharmacopsychiatry 39(6):205-208
54. Buckley AW, Sassower K, Rodriguez AJ, Jennison K, Wingert K, Buckley J, Thurm A, Sato S, Swedo S (2011) An open label trial of donepezil for enhancement of rapid eye movement sleep in young children with autism spectrum disorders. J Child Adolesc Psychopharmacol 21(4):353-357. doi: 10.1089/cap.2010.0121
55. Sukys-Claudino L, Moraes W, Guilleminault C, Tufik S, Poyares D (2012) Beneficial effect of donepezil on obstructive sleep apnea: a double-blind, placebo-controlled clinical trial. Sleep Med 13(3):290-296. doi: 10.1016/j.sleep.2011.09.014
56. Niederhofer HJ (2006) Donepezil in the treatment of narcolepsy. Clin Sleep Med 2(1):71-72
57. Ringman JM, Simmons JH (2000) Treatment of REM sleep behavior disorder with donepezil: a report of three cases. Neurology 55(6):870-871
58. Wisor JP, Edgar DM, Yesavage J, Ryan HS, McCormick CM, Lapustea N, Murphy GM Jr (2005) Sleep and circadian abnormalities in a transgenic mouse model of Alzheimer's disease: a role for cholinergic transmission. Neuroscience 131(2):375-385
59. Moraes Wdos S, Poyares DR, Guilleminault C, Ramos LR, Bertolucci PH, Tufik S (2006) The effect of donepezil on sleep and REM sleep EEG in patients with Alzheimer disease: a double-blind placebo-controlled study. Sleep 29(2):199-205
60. Schredl M, Weber B, Braus D, Gattaz WF, Berger M, Riemann D, Heuser I (2000) The effect of rivastigmine on sleep in elderly healthy subjects. Exp Gerontol 35(2):243-249
61. Di Giacopo R, Fasano A, Quaranta D, Della Marca G, Bove F, Bentivoglio AR (2012) Rivastigmine as alternative treatment for refractory REM behavior disorder in Parkinson's disease. Mov Disord 27(4):559-561. doi: 10.1002/mds.24909
62. Terzaghi M, Rustioni V, Manni R, Pacchetti C, Zangaglia R, Ossola M (2010) Agrypnia with nocturnal confusional behaviors in dementia with Lewy bodies: immediate efficacy of rivastigmine. Mov Disord 25(5):647-649. doi: 10.1002/mds.22726
63. Maclean LE, Collins CC, Byrne EJ (2001) Dementia with Lewy bodies treated with rivastigmine: effects on cognition, neuropsychiatric symptoms, and sleep. Int Psychogeriatr 13(3):277-288
64. Pavlis CJ, Kutscher EC, Carnahan RM, Kennedy WK, Van Gerpen S, Schlenker E (2007) Rivastigmine-induced dystonia. Am J Health Syst Pharm 64(23):2468-2470
65. Nozaki I, Inao G, Yamada M (2007) Donepezil-induced chorea in Alzheimer's disease. J Neurol 254(12):1752-1753
66. Leelavathi M, Rosdinom R, Suguna M (2012) Pisa syndrome secondary to rivastigmine: a case report. Clin Ter 163(1):31-32
67. Mumoli N, Carmignani G, Luschi R, Cei M, Chiavistelli P (2009) Hepatitis with cholestasis caused by rivastigmine transdermal patch. Am J Gastroenterol 104(11):2859-2860
68. Dierckx RI, Vandewoude MF (2008) Donepezil-related toxic hepatitis. Acta Clin Belg 63(5):339-342
69. Sink KM, Thomas J, Xu H, Craig B, Kritchevsky S, Sands LP (2008) Dual use of bladder anticholinergics and cholinesterase inhibitors: long-term functional and cognitive outcomes. J Am Geriatr Soc 56:847-853
70. Jones RW (2010) A review comparing the safety and tolerability of memantine with the acetylcholinesterase inhibitors. Int J Geriatr Psychiatry 25(6):547-553
71. Ferrara N, Corbi G, Capuano A, Filippelli A, Rossi F (2008) Memantine-induced hepatitis with cholestasis in a very elderly patient. Ann Intern Med 148(8):631-632
72. (2009) Memantine: heart failure: harmful drug. Prescrire Int 18(102):167 (no authors listed)
73. Gareri P, De Sarro G (2012) Principi di farmacologia geriatrica. In: Putignano S., Cester A., Gareri P. Geriatria nel territorio - un metodo per i vecchi, per i medici e per il futuro. Critical Medicine Publishing s.r.l., Roma: 2012 (book chapter) pp 361-404
74. Tiseo PJ, Foley K, Friedhoff LT (1998) The effect of multiple doses of donepezil HCl on the pharmacokinetic and pharmacodynamic profile of warfarin. Br J Clin Pharmacol 46(Suppl 1):45-50
75. Jones RW (2010) A review comparing the safety and tolerability of memantine with the acetylcholinesterase inhibitors. Int J Geriatr Psychiatry 24:547-553